[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 4 sources · 3 days · First seen · Last updated

Akebia Therapeutics Q2 financial and clinical results

Overview

Akebia Therapeutics reported second-quarter results characterized by a significant divergence in product performance. Revenue for its anemia drug, Vafseo, grew 60% year-over-year to $21.3 million, supported by a 41% sequential increase in active patients. Conversely, total company revenue fell 21.5% to $49.1 million, largely due to Auryxia sales dropping from $47.2 million to $25.5 million amid pricing pressure and generic competition.

The company also shared results from its VOICE trial involving 2,116 patients. The study met predefined stopping criteria, showing a statistically significant 10% reduction in the composite endpoint of all-cause mortality and hospitalization. CEO John Butler stated the results “confirmed the drug’s efficacy and supported continued commercial expansion.”

Entities

McCormick & Company, Incorporated · Akebia Therapeutics · Auryxia · John Butler · VOICE trial

Timeline

  1. 2 days ago

    [BUSINESS] 3 sources
    Axsome Therapeutics reports 46% revenue growth in Q2 2026

    Axsome Therapeutics reported Q2 2026 net product revenue of $218.4 million, up 46% year over year, driven by strong AUVELITY sales despite a quarterly net loss of $51.3 million.

  2. 5 days ago

    [BUSINESS] 2 sources
    Akebia Therapeutics reports Vafseo growth and Auryxia sales decline in Q2

    Akebia Therapeutics posted Q2 growth for Vafseo, with revenue up 60% to $21.3 M and 10,500 patients, while Auryxia sales fell 46% to $25.5 M. An interim VOICE trial showed mortality and hospitalization cuts, sp

Sources

it-boltwise.de · seekingalpha.com · stocknews.com · stocktitan.net